Documents
-
- Download
- Title Page_Contents
-
open access
-
- Download
- Chapter 01
-
open access
-
- Download
- Chapter 02
-
open access
- Full text at publishers site
-
- Download
- Chapter 03
-
open access
- Full text at publishers site
-
- Download
- Chapter 04
-
open access
-
- Download
- Chapter 05
-
open access
- Full text at publishers site
-
- Download
- Chapter 06
-
open access
- Full text at publishers site
-
- Download
- Chapter 07
-
open access
- Full text at publishers site
-
- Download
- Chapter 08
-
open access
- Full text at publishers site
-
- Download
- Chapter 09
-
open access
- Full text at publishers site
-
- Download
- Chapter 10
-
open access
-
- Download
- Chapter 11
-
open access
- Full text at publishers site
-
- Download
- Chapter 12
-
open access
-
- Download
- Chapter 13
-
open access
-
- Download
- Summary_in Dutch
-
open access
-
- Download
- Appendices
-
open access
-
- Download
- Propositions
-
open access
In Collections
This item can be found in the following collections:
Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics
Fluoropyrimidines, such as 5-fluorouracil (5-FU) and capecitabine, are among the most frequently prescribed anticancer drugs. They are inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). Up to 5% of the population is DPD deficient and these patients have a significantly increased risk of severe and potentially lethal toxicity when treated with regular doses of 5-FU or capecitabine. DPD is encoded by the gene DPYD and variants in DPYD can lead to a decreased DPD activity. Although prospective DPYD genotyping is a valuable tool to identify patients with DPD deficiency, and thus those at risk for severe and potential life-threatening toxicity, prospective genotyping has not yet been implemented in daily clinical care.
With this thesis we improved knowledge on different aspects of DPYD genotyping and DPD phenotyping, in order to better predict DPD deficient patients and personalize their therapy. In addition, we improved clinical implementation of DPYD genotyping,...
Show moreFluoropyrimidines, such as 5-fluorouracil (5-FU) and capecitabine, are among the most frequently prescribed anticancer drugs. They are inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). Up to 5% of the population is DPD deficient and these patients have a significantly increased risk of severe and potentially lethal toxicity when treated with regular doses of 5-FU or capecitabine. DPD is encoded by the gene DPYD and variants in DPYD can lead to a decreased DPD activity. Although prospective DPYD genotyping is a valuable tool to identify patients with DPD deficiency, and thus those at risk for severe and potential life-threatening toxicity, prospective genotyping has not yet been implemented in daily clinical care.
With this thesis we improved knowledge on different aspects of DPYD genotyping and DPD phenotyping, in order to better predict DPD deficient patients and personalize their therapy. In addition, we improved clinical implementation of DPYD genotyping, and reduced the risk of severe fluoropyrimidine-induced toxicity in DPYD variant allele carriers.
Show less- All authors
- Lunenburg, C.A.T.C.
- Supervisor
- Gelderblom, A.J.; Guchelaar, H.-J.
- Co-supervisor
- Swen, J.J.
- Committee
- Beijnen, J.H.; Cobbaert, C.M.; Gietema, J.A.
- Qualification
- Doctor (dr.)
- Awarding Institution
- Medische Oncologie & Klinische Farmacie en Toxicologie , Medicine / Leiden University Medical Center (LUMC) , Leiden University
- Date
- 2019-06-11
- ISBN (print)
- 9789463325004